Pulmonary Hypertension
Conditions
Brief summary
Evaluation of the prevalence of kidney disease, hemodynamic predictors and long-term renal outcome in patients with invasively diagnosed pulmonary hypertension.
Detailed description
This study aims to determine the prevalence of kidney disease, hemodynamic predictors and long-term renal outcome of in-hospital patients with invasively diagnosed pulmonary hypertension at the Department of Pulmonology, University Hospital Giessen and Marburg, Giessen, Germany between 1999 and 2016.
Interventions
OTHERNo intervention
No intervention
Sponsors
University of Giessen
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* older than 18 years * subjects with invasively diagnosed pulmonary hypertension at rest and available renal function and spot urine data at day of right heart catheterization between March 1999 and December 2016 at the Department of Pulmonology, University Hospital Giessen and Marburg, Giessen, Germany
Exclusion criteria
* subjects with estimated GFR \<15ml/min/1.73m2 or prior dialysis * pre-existing acute kidney injury * non-end stage renal disease with extracorporeal or peritoneal ultrafiltration due to diuretic-resistant fluid overload * primary kidney disease requiring active immunosuppression * autosomal dominant polycystic kidney disease * if subjects are pregnant * if subjects are recipients of solid-organ transplants * subjects with pulmonary hypertension with unclear/multifactorial mechanisms (WHO group 5 pulmonary hypertension)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in estimated glomerular filtration rate (GFR) in each class of pulmonary hypertension during follow-up period | 3 years follow-up | Estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) will be used over follow-up period to determine changes in renal function |
| Impact of renal function on deterioration of pulmonary hypertension during follow-up period | 3 years follow-up | Changes in estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) over follow-up period will be correlated with clinical worsening of pulmonary hypertension (as determined by echocardiography, 6-minute-walk, New York Heart Association classification, b-type natriuretic peptide) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact of pulmonary hypertension-related morbidity on renal function decline | 3 years follow-up | Severity of pulmonary hypertension (progress pulmonary hypertension, unscheduled hospitalization due to worsening of pulmonary hypertension, mortality) will be correlated with changes in renal function (as determined by estimated GFR \[Chronic Kidney Disease Epidemiology Collaboration\]) |
| Prevalence of proteinuria in pulmonary hypertension | At baseline | 24 hours urine collection at baseline will be assessed to predict progress of pulmonary hypertension |
| Impact of pulmonary hypertension-specific therapy on renal function decline | 3 years follow-up | Estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) over follow-up period will be assessed to show association of pulmonary hypertension-specific therapy on renal function |
Countries
Germany
Outcome results
None listed